Results 41 to 50 of about 2,034 (179)
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. [PDF]
PLoS ONE, 2011 Aberrant histone deacetylase (HDAC) activity is frequent in human leukemias. However, while classical, NAD(+)-independent HDACs are an established therapeutic target, the relevance of NAD(+)-dependent HDACs (sirtuins) in leukemia treatment remains ...
Michele Cea +23 more
doaj +1 more source
FK866 inhibits the epithelial‑mesenchymal transition of hepatocarcinoma MHCC97‑H cells
Oncology Letters, 2018 Epithelial-mesenchymal transition (EMT) is known to serve a pivotal function in hepatocellular carcinoma (HCC) metastasis. Nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in the nicotinamide-adenine dinucleotide (NAD+)-mediated pathway for the activation of silent information regulator 1 (SIRT1), serves a key function in HCC cell ...
Zhang, Bin +5 more
openaire +3 more sources
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
Oncotarget, 2016 Treating pancreatic cancer is extremely challenging due to multiple factors, including chemoresistance and poor disease prognosis. Chemoresistance can be explained by: the presence of a dense stromal barrier leading to a lower vascularized condition, therefore limiting drug delivery; the huge intra-tumoral heterogeneity; and the status of epithelial-to-
Barraud, Marine +23 more
openaire +3 more sources
NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma
Molecular Therapy: Oncolytics, 2022 Cancer cell energy metabolism plays an important role in dictating the efficacy of oncolysis by oncolytic viruses. To understand the role of multiple myeloma metabolism in reovirus oncolysis, we performed semi-targeted mass spectrometry-based ...
Barry E. Kennedy +17 more
doaj +1 more source
Cancer & Metabolism, 2018 Background Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide, exhibit anticancer effects in preclinical models.
Natthakan Thongon +12 more
doaj +1 more source
Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors
Pharmaceuticals, 2022 NAPRT, the rate-limiting enzyme of the Preiss–Handler NAD biosynthetic pathway, has emerged as a key biomarker for the clinical success of NAMPT inhibitors in cancer treatment. Previous studies found that high protein levels of NAPRT conferred resistance
Jorge Franco +14 more
doaj +1 more source
Attenuates of NAD+ impair BMSC osteogenesis and fracture repair through OXPHOS
Stem Cell Research & Therapy, 2022 Background Controlling the adipo-osteogenic lineage commitment of bone marrow mesenchymal stem cell (BMSC) in favor of osteogenesis is considered a promising approach for bone regeneration and repair.
Boer Li +7 more
doaj +1 more source
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells [PDF]
International Journal of Cancer, 2012 AbstractFK866 is a specific inhibitor of NAMPT and induces apoptosis of leukemic cells by depletion of intracellular NAD+. Since up‐regulation of NAMPT is associated with several cases of cancers, including leukemias, we asked whether in leukemic cells inhibition of NAMPT involves p53 pathway.
Thakur, Basant Kumar +7 more
openaire +2 more sources
Annals of Hepatology, 2022 Introduction and Objectives: Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme on the NAD+ salvage biosynthetic pathway and a cytokine regulator with an important role in inflammation and fibrogenesis modulation.
J.A. Gutiérrez buendía +10 more
doaj +1 more source
, 2013 10 mg/kg body weight FK866 were administered to mice from day 12 after rMOG immunization for 10 days. A, NAD(H) and NADP(H) levels were measured in mononuclear cells isolated from spleen and lymph nodes of treated or untreated animals at day 16 ...
Eva Moran (212204) +18 more
core +1 more source